Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.46 |
| ▸ | SRC | P12931 | 7/20 | 0.46 |
| ▸ | VNN1 | O95497 | 6/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | YES1 | P07947 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | HCK | P08631 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | FRK | P42685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17420219 | 0.85 | ABL1 (0.53) | ABL1SRCEGFRLCKFYN | |
| SCHEMBL15859863 | 0.85 | BRAF (0.52) | ABL1EGFRBCRBRAF | |
| SCHEMBL15859858 | 0.85 | ABL1 (0.43) | ABL1SRCVNN1EGFRLCK | |
| SCHEMBL15859879 | 0.81 | ABL1 (0.48) | ABL1EGFRLCKFYNLYN | |
| SCHEMBL15859802 | 0.75 | ABL1 (0.58) | ABL1SRCKCNQ3KCNQ2KCNE1 | |
| SCHEMBL17420225 | 0.75 | ABL1 (0.53) | ABL1SRCKCNQ3KCNQ2 | |
| SCHEMBL15859909 | 0.75 | ABL1 (0.66) | ABL1SRCEGFRLCKFYN | |
| SCHEMBL15859950 | 0.74 | ABL1 (0.44) | ABL1SRCEGFRLCKFYN | |
| SCHEMBL15859804 | 0.73 | BRAF (0.56) | ABL1SRCEGFRLCKFYN | |
| SCHEMBL15859862 | 0.72 | ABL1 (0.55) | ABL1EGFRBCRBRAFPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
| WO-2014102376-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2014-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | ABL1 128/4885SRC 199/4885VNN1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.